Table 4.
Univariate and multivariate analyses for time to grade 2 or higher GU toxicity
| Characteristic | HR | 95% CI; p value |
|---|---|---|
| Univariate analysis Cohort | ||
| HDR | - | |
| LDR | 7.86 | 3.19,19.4; <0.001 |
| Age | 1.02 | 0.97, 1.07; 0.4 |
| Prostate volume | 0.98 | 0.95,1.01; 0.2 |
| Baseline IPSS | 0.94 | 0.85–1.04; 0.2 |
| Baseline urinary medication | 2.03 | 0.77–5.32; 0.2 |
| ADT use | ||
| No | - | |
| Yes | 0.46 | 0.16–1.33; 0.2 |
| Multivariate analysis Cohort | ||
| HDR | - | - |
| LDR | 8.14 | 2.82–23.5; <0.001 |
HR = hazard ratio; HDR = high-dose-rate; LDR = low-dose-rate; IPSS = international prostate symptom score; ADT = androgen deprivation therapy.